Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2020 08:00 ET | Source: Everest Medicines

云顶新耀宣布中国国家药品监督管理局批准sacituzumab govitecan临床试验申请，将启动治疗转移性三阴性乳腺癌中国注册临床研究

此项临床试验的获批允许云顶新耀将患者纳入中国注册临床研究美国食品和药物管理局已授予sacituzumab govitecan 快速审定通道与突破性疗法认定，用于既往治疗无效的转移性三阴性乳腺癌患者中国上海, April 22, 2020 (GLOBE NEWSWIRE) -- 中国上海 – 2020年4月22日 – 云顶新耀（Everest...
April 17, 2020 06:00 ET | Source: Everest Medicines

云顶新耀宣布用于治疗复杂性腹腔内感染抗菌药物Xerava™获得新加坡卫生科学局批准

中国上海, April 17, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest Medicines），一家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港特别行政区、澳门特别行政区以及台湾地区）及其它亚洲市场未满足的医疗需求，今天宣布新加坡卫生科学局（HSA）已批准用于治疗成人复杂性腹腔内感染（cIAI）的抗菌素Xerava™...
April 17, 2020 06:00 ET | Source: Everest Medicines

Everest Medicines Announces Approval of Xerava™ from the Health Science Authority in Singapore for the Treatment of Complicated Intra-Abdominal Infections

SHANGHAI, China, April 17, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
April 09, 2020 06:00 ET | Source: Everest Medicines

云顶新耀宣布其 taniborbactam (VNRX-5133)联合头孢吡肟体外研究取得积极成果

中国上海, April 09, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest Medicines)，一家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港特别行政区、澳门特别行政区以及台湾地区）及其它亚洲市场未满足的医疗需求，今日公布其taniborbactam (VNRX-5133)联合头孢吡肟的体外研究试验结果。此项研究评估了新型β-...
April 09, 2020 06:00 ET | Source: Everest Medicines

Everest Medicines Announces Positive Results from In Vitro Study of Taniborbactam (VNRX-5133) in Combination with Cefepime

SHANGHAI, China, April 09, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
March 17, 2020 06:00 ET | Source: Everest Medicines

云顶新耀与嘉善国家级经济技术开发区和嘉善国投达成战略合作

云顶新耀将在嘉善国家级经济技术开发区成立中国总部和全球生产基地获嘉善国投1亿美金投资，主要用于支持云顶新耀在中国的药物研发、GMP生产基地和GSP设施建设等中国上海, March 17, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest...
March 17, 2020 06:00 ET | Source: Everest Medicines

Everest Medicines Forms Strategic Partnership with Jiashan National Economic and Technological Development Zone and Jiashan SDIC

Everest Medicines to place its China holding company and global manufacturing site in Jiashan National Economic and Technological Development ZoneUS $100 million investment from Jiashan SDIC to...
February 20, 2020 05:30 ET | Source: Everest Medicines

Everest Medicines任命医学博士Kerry Blanchard出任董事兼首席执行官

•新任首席执行官将以丰富的经验和专业知识，带领公司进入下一增长阶段，继续开发满足大中华地区医疗需求的创新医药 •代理首席执行官曹武雄将转任执行领导团队高级顾问，以支持管理层平稳过渡中国上海, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Everest...
February 20, 2020 05:30 ET | Source: Everest Medicines

Everest Medicines Appoints Kerry Blanchard, M.D., Ph.D., as Director and Chief Executive Officer

New CEO brings deep experience and expertise to lead company into next phase of growth as it continues to develop therapies for critical unmet needs in Greater ChinaInterim CEO Sean Cao will...
December 18, 2019 12:01 ET | Source: Everest Medicines

Everest Medicines Announces Approval of Nefecon’s Clinical Trial Application by the China National Medical Products Administration

SHANGHAI, China, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...